

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (canceled)

Claim 2 (previously withdrawn)

Claim 3 (previously withdrawn)

Claim 4 (previously withdrawn)

Claim 5 (canceled)

Claim 6 (canceled)

Claim 7 (canceled)

Claim 8 (previously withdrawn)

Claim 9 (previously withdrawn)

Claim 10 (previously withdrawn)

Claim 11 (previously withdrawn)

Claim 12 (canceled)

Claim 13 (canceled)

Claim 14 (Currently Amended): A method for prevention ~~and~~ or treatment of atherosclerosis in a subject, comprising administering a therapeutically effective amount of an immunological oral tolerance-inducing composition comprising one or more ~~an~~ active components selected from the group consisting of modified low density lipoprotein, oxidized low density lipoprotein (Ox LDL), heat shock protein 60/65 (HSP 60/65), beta₂-glycoprotein-1 (β₂GP-1)[,] or functional derivatives thereof and ~~mixtures thereof, in combination with~~ a pharmaceutically acceptable carrier for oral administration, wherein said administration is in a sufficient amount to induce

production of TGF β , to suppress IFN- γ , and to suppress a type 1 T-cell cytokine pattern
thereby inhibiting at least one atherosclerosis-related symptom in said subject.

Claim 15 (previously withdrawn)

Claim 16 (previously withdrawn)

Claim 17 (previously withdrawn)

Claim 18 (currently amended) A The method according to claim 14, wherein said active component is modified low-density lipoprotein.

Claim 19 (currently amended) A The method according to claim 14, wherein said active component is oxidized low density lipoprotein (Ox LDL).

Claim 20 (original): The method according to claim 14, wherein said active component is a functional derivative of oxidized low density lipoprotein (Ox LDL).

Claim 21 (previously withdrawn)

Claim 22 (previously withdrawn)

Claim 23 (previously withdrawn)

Claim 24 (previously withdrawn)

Claim 25 (canceled)

Claim 26 (previously amended): The method according to claim 14, wherein said functional derivative is malondialdehyde LDL (MDA-LDL).